Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01365546 · ClinicalTrials.gov registry record · Phase 3

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

A Phase 3 study of Prevent Bleeding in Major Surgery, sponsored by Octapharma.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target
15
Study locations

NCT01365546 is a Phase 3 study of Prevent Bleeding in Major Surgery that has completed, run by Octapharma. The registered enrollment target is 30 participants. The trial reports 15 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01365546, a Phase 3 study of Prevent Bleeding in Major Surgery, has completed, sponsored by Octapharma.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target
15
Study locations

Study Summary

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Interventions

  • BIOLOGICAL human VWF/FVIII concentrate

Study Locations (15)

Other

  • SHAT Joan Pavel - Sofia
  • Azienda Ospedaliero Universitaria Careggi - Florence
  • Granda Ospedale Maggiore Policlinico - Milan
  • ULSS6 Vicenza Ematologia - Vicenza
  • Sultan Quaboos University Hospital - Muscat
  • Instytut Hematologii i Transfuzjologii - Warsaw
  • Fundeni Clinical Institute - Bucharest
  • Louis Turcanu Childrens Emergency Hospital - Timișoara
  • Hemophilia Comprehensive Care Center - Johannesburg
  • Ege University - Izmir

Indiana

  • Indiana Hemophilia and Thrombosis Center - Indianapolis

North Carolina

  • UNC-CH Comprehensive Hemophilia Center - Chapel Hill

Wisconsin

  • Blood Center of Wisconsin - Milwaukee

Pune

  • Sahyadri Specialty Hospital - Pune

Tamil Nadu

  • Christian Medical College - Vellore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-06
Est. Completion 2014-04
Phase Phase 3

Sponsor

Octapharma

43 total trials

What the Registry Record Tells You About NCT01365546

The ClinicalTrials.gov registry entry for NCT01365546 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prevent Bleeding in Major Surgery appearing as the primary indexed condition, and to 1 intervention - of which human VWF/FVIII concentrate is the first listed.

NCT01365546 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Other, Indiana, North Carolina.

Frequently Asked Questions

What is clinical trial NCT01365546 about?

NCT01365546 is a clinical study titled "Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery". Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

What is the current status of trial NCT01365546?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2014-04.

What conditions does trial NCT01365546 study?

This clinical trial studies the following conditions: Prevent Bleeding in Major Surgery.

What interventions are being tested in trial NCT01365546?

The interventions under investigation include: human VWF/FVIII concentrate (BIOLOGICAL).

Who is sponsoring clinical trial NCT01365546?

This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01365546 being conducted?

This trial has 15 study locations across Indiana, North Carolina, Wisconsin, Pune, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.